# Which funds hold Kardium?

From the SEC Form N-PORT filings of US funds, periods ended 2026-05-31 to 2026-07-31.

Canonical page: https://tickerinside.com/private-companies/kardium/
Licence: CC BY 4.0, attribution to TickerInside.

On their latest SEC filings, 20 US funds held Kardium, worth $168 million in all. Select Medical Technology and Devices Portfolio (FSMEX) held the most: $31.1 million, 1.04% of the fund, for the period ended May 31, 2026. The funds that give a share count valued one share at $0.4800 to $1.07, $0.8192 at the median. The first fund to report it held it in Q3 2019; 20 held it in Q2 2026.

- Funds holding it: 20
- Value held, as the funds value it: $168 million
- Largest holder: Select Medical Technology and Devices Portfolio, $31.1 million
- ETFs holding it: none

## By quarter

| Quarter | Funds | Value held |
|---|---:|---:|
| Q2 2026 | 20 | $168M |
| Q1 2026 | 23 | $210M |
| Q4 2025 | 24 | $210M |
| Q3 2025 | 24 | $213M |
| Q2 2025 | 23 | $214M |
| Q1 2025 | 19 | $121M |
| Q4 2024 | 20 | $120M |
| Q3 2024 | 20 | $121M |
| Q2 2024 | 18 | $88.7M |
| Q1 2024 | 16 | $90.6M |
| Q4 2023 | 16 | $99.1M |
| Q3 2023 | 16 | $112M |
| Q2 2023 | 16 | $112M |
| Q1 2023 | 16 | $112M |
| Q4 2022 | 16 | $107M |
| Q3 2022 | 16 | $107M |
| Q2 2022 | 16 | $107M |
| Q1 2022 | 16 | $113M |
| Q4 2021 | 16 | $113M |
| Q3 2021 | 16 | $113M |
| Q2 2021 | 16 | $113M |
| Q1 2021 | 16 | $113M |
| Q4 2020 | 5 | $18.4M |
| Q3 2020 | 5 | $13.6M |
| Q2 2020 | 5 | $13.6M |
| Q1 2020 | 5 | $13.7M |
| Q4 2019 | 5 | $18.4M |
| Q3 2019 | 4 | $17.9M |

## Every fund holding Kardium

| Fund | Tickers | Value | Of the fund | Per share | Period ended | Security |
|---|---|---:|---:|---:|---|---|
| Select Medical Technology and Devices Portfolio | FSMEX | $31.1M | 1.04% | $0.8500 to $1.07 | 2026-05-31 | Series E preferred |
| T. Rowe Price Health Sciences Fund, Inc. | PRHSX, THISX | $29.6M | 0.25% | $0.6472 to $0.8274 | 2026-06-30 | Series D6 preferred, Series D-7 preferred, Series D-5 preferred, Series D-8 preferred |
| T. Rowe Price New Horizons Fund, Inc. | PRJIX, PRNHX | $22.8M | 0.15% | $0.8192 to $0.8274 | 2026-06-30 | Series D6 preferred, Series D-5 preferred |
| Fidelity Growth Company Fund | FDGRX, FGCKX | $19.1M | 0.02% | $0.5200 to $1.07 | 2026-05-31 | Series E preferred |
| T. Rowe Price Small-Cap Stock Fund, Inc. | OTCFX, OTIIX | $15.8M | 0.17% | $0.6472 to $0.8274 | 2026-06-30 | Series D-7 preferred, Series D6 preferred, Series D-8 preferred |
| Eventide Healthcare & Life Sciences Fund | ETAHX, ETCHX | $10.8M | 0.60% | $0.7000 | 2026-06-30 | Preferred shares |
| Select Health Care Portfolio | FHCLX, FHCNX | $10.4M | 0.18% | $0.5200 | 2026-05-31 | Series E preferred |
| T. Rowe Price Institutional Small-Cap Stock Fund | TRSSX | $8.1M | 0.16% | $0.6472 to $0.8274 | 2026-06-30 | Series D-7 preferred, Series D6 preferred, Series D-8 preferred |
| Fidelity Advisor Health Care Fund | FACDX, FACTX | $6.0M | 0.19% | $0.4800 to $0.4900 | 2026-07-31 | Series E preferred |
| Fidelity Growth Company K6 Fund | FGKFX | $4.8M | 0.02% | $0.5200 to $1.07 | 2026-05-31 | Series E preferred |
| Fidelity Series Growth Company Fund | FCGSX | $4.1M | 0.02% | $0.5200 to $1.07 | 2026-05-31 | Series E preferred |
| VIP Health Care Portfolio |  | $1.6M | 0.14% | $0.5200 | 2026-06-30 | Series E preferred |
| T. Rowe Price Health Sciences Portfolio | QAAGZX, QAAHBX | $1.4M | 0.19% | $0.6472 to $0.8274 | 2026-06-30 | Series D6 preferred, Series D-7 preferred, Series D-5 preferred, Series D-8 preferred |
| VIP Stock Selector Portfolio |  | $785,086 | 0.02% | $0.5200 | 2026-06-30 | Series E preferred |
| Science & Technology Fund | VCSTX | $555,257 | 0.01% | $1.02 | 2026-05-31 | Series D preferred |
| T. Rowe Price Spectrum Moderate Growth Allocation Fund | TGIPX, TRSGX | $384,416 | 0.01% | $0.6472 to $0.8274 | 2026-05-31 | Series D-7 preferred, Series D-8 preferred, Series D6 preferred |
| T. Rowe Price Spectrum Moderate Allocation Fund | TPPAX, TRPBX | $183,391 | 0.01% | $0.6472 to $0.8274 | 2026-05-31 | Series D-7 preferred, Series D6 preferred, Series D-8 preferred |
| T. Rowe Price Spectrum Conservative Allocation Fund | PPIPX, PRSIX | $117,680 | 0.01% | $0.6472 to $0.8274 | 2026-05-31 | Series D-7 preferred, Series D6 preferred, Series D-8 preferred |
| Small Cap Growth Fund | VVSGX | $60,238 | 0.01% | $1.02 | 2026-05-31 | Series D6 preferred |
| T. Rowe Price Moderate Allocation Portfolio | QAAGRX | $16,721 | 0.01% | $0.6472 to $0.8274 | 2026-06-30 | Series D-7 preferred, Series D-8 preferred, Series D6 preferred |

## Other private companies US funds hold

- Anthropic: https://tickerinside.com/private-companies/anthropic/ (110 funds)
- Databricks: https://tickerinside.com/private-companies/databricks/ (98 funds)
- Sila Nanotechnologies: https://tickerinside.com/private-companies/sila-nano/ (23 funds)
- Fanatics: https://tickerinside.com/private-companies/fanatics/ (21 funds)
- Lightmatter: https://tickerinside.com/private-companies/lightmatter/ (20 funds)
- Tenstorrent: https://tickerinside.com/private-companies/tenstorrent/ (20 funds)
- ElevateBio: https://tickerinside.com/private-companies/elevatebio/ (20 funds)
- Long Wall (ABL Space Systems): https://tickerinside.com/private-companies/long-wall/ (20 funds)

## Where these figures come from

A holding is a fund's common or preferred share of a company that is not listed: valued with unobservable inputs (fair value level 3) and placed privately (a restricted security, or PP in its title), never a right left from a takeover, an escrow, or a vehicle that holds such shares. A company that funds hold as a listed share in the same data set is public and left out. Rows are joined into a company by its name, its share class and legal form cut off. Each fund values its shares itself, every quarter, so two funds can value one share differently.

## Use this data

- This company: https://tickerinside.com/api/v1/private-companies/kardium.json
- Every company: https://tickerinside.com/api/v1/private-companies.json

## Cite this page

TickerInside, funds holding Kardium, from SEC Form N-PORT (2026q3 data set), https://tickerinside.com/private-companies/kardium/

Each value is the fund's own estimate of a share no market quotes, from its latest public SEC Form N-PORT. Measurements of public filings, not investment advice and not a way to buy a share.